PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. (“Pacira” or “the Company”) PCRX for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before March 14, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Pacira issued a press release on August 9, 2024, announcing the results of its patent lawsuit against eVenus. The Company announced that the court “found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid,” meaning that eVenus did not infringe on it. The patent at the heart of the lawsuit is for Exparel, the main source of the Company’s growth accounting for 80% of its revenue. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Pacira, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.